Trauma and Stressor Related Disorders
Conditions
Keywords
Transcranial Magnetic Stimulation, Chronic Trauma and Stressor Related Disorders, Veterans RAND 36-item health survey (VR-36), Health Related Quality of Life, EEG, Alpha Rhythms
Brief summary
The goal of this clinical trial is to learn about the safety, feasibility, and preliminary efficacy of EEG-enhanced transcranial magnetic stimulation (eTMS) as an adjunct to standard-of-care therapies for chronic trauma and stressor related disorders (TSRD) among US military veterans. The main questions the study aims to answer are: * Is it safe to provide 30 sessions of eTMS for veterans with chronic TSRD? * Is it feasible to provide 30 sessions of eTMS as an adjunct to standard-of-care therapies for veterans with chronic TSRD? * Does health-related quality of life improve among veterans after 30 sessions of eTMS as an adjunct to standard-of-care therapies for chronic TSRD? Participants will undergo 30 sessions of eTMS as an adjunct to standard-of-care therapies for veterans with chronic TSRD, weekly reassessment during treatment, and intermittent follow-up for 36 weeks post-enrollment.
Interventions
DEVICEAdjunctive, midline prefrontal, lower intensity, shorter session, EEG-enhanced, repetitive transcranial magnetic stimulation (eTMS)
Approximately 2000 pulses per session (x30 sessions) of midline prefrontal, repetitive transcranial magnetic stimulation at 50% or less of motor threshold, calibrated via EEG to a resonant alpha frequency of the participant, and given over approximately 12 minutes. Given as an adjunct to standard of care and integrative treatment for TSRD.
Sponsors
Marcia Bockbrader, MD PhD
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This will be a staged, open-label, Phase II/III safety, feasibility, and efficacy investigational device trial. A staged approach will be utilized to assess safety, feasibility, and preliminary efficacy with 30 participants with an interim analysis after data collection at 6 weeks. If safety benchmarks are passed, the study will proceed with Stage 2, in which an additional 270 participants will be enrolled using randomization to multiple baselines for efficacy analyses.
Eligibility
Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Positive identification as a Veteran per discharge paperwork (DD-214, DD-215, NGB-22, NGB-22A) and photo ID, or Veterans Health Administration Veteran Health Identification Card (VHIC) * Presence of deployment-related stressful events (as defined by the Deployment Risk & Resilience Inventory-2, DRRI-2) * Trauma event(s) (defined on the Life Experiences Checklist for DSM-5, LEC-5) * Presence of 6 months or more of 6 or more moderate or worse symptoms from any of the five categories associated with stress disorders as operationalized on the PTSD Checklist for DSM-5 (PCL-5; intrusion, altered mood and cognitions, dissociation, avoidance, and arousal). * Informed consent for study participation, off label-eTMS, and data use * Enrollment in addiction services, if meets standard addiction treatment criteria * Enrollment in opioid reduction services, if dependent on opioids and morphine equivalent daily dose exceeds 50 mg (50 morphine equivalent daily dose, MEDD) * Agreement to limit daily alcoholic beverage consumption to no more than 2 servings * Signed pain contract, if MEDD \>= 80, per State of Ohio prescribing guidelines
Exclusion criteria
* Uncontrolled medical, psychological or neurological conditions including, but not limited to: * Uncontrolled psychosis or mania * Uncontrolled seizure disorder or EEG abnormalities that indicate risk of seizure, i.e., epileptiform discharges during the EEG recording * Uncontrolled cardiac, pulmonary, or endocrine disorder (e.g., diabetes) * Acute pain or illness * Active, untreated addiction to prescription drugs, alcohol or illicit substances (not including cannabis or derivatives, which are available in many states under medical prescription or for recreational use) * Clinically significant medical condition or abnormality that in the Investigator's judgment might pose a potential safety risk to the subject or limit the interpretation of the trial results * Pregnant, or female unwilling to use effective birth control during the course of the trial (unless cleared for participation by obstetrician/gynecologist) * Absolute contraindications to TMS: Presence of aneurysm clips or coils, cochlear or ocular implant, cortical epidural stimulator, deep brain stimulator, pacemaker or defibrillator, retained intracranial metal foreign body (bullets, shrapnel - excluding titanium and oral implants), steel stents or shunts, active vagal nerve stimulator, ventriculoperitoneal (VP) shunt. * Prior TMS treatment * Unwilling or unable to adhere to the study treatment, data collection schedule, or study procedures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with device-related serious adverse events | 6 weeks | To address safety of the procedure, the study investigators will report number of participants (of 30 initial cohort) with expected, device-related serious adverse events (SAE's) or unexpected, device-related SAE's during treatment |
| Rate of participants completing 80% of scheduled visits | 6 weeks | To assess feasibility of the procedure, the study investigators will report the rate of participants (for initial cohort of 30) completing \>= 80% of the 30 scheduled eTMS sessions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean change in Veterans RAND 36-item health survey (VR-36) mental component scores (MCS) | 6 weeks | To assess efficacy of the procedure to improve health related quality of life, the study investigators will report the mean change from baseline to week 6 in mental component score (MCS) on Veterans RAND 36-item health survey (VR-36) for participants (in initial cohort of 30) who completed \>=80% of eTMS sessions |
Countries
United States
Contacts
Primary ContactMarcia A Bockbrader, MD, PhD
Backup ContactNeil B Austin
Outcome results
None listed